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Recalcitrant In-Drug-Eluting
Stent Restenosis*
Julinda Mehilli, MD, David Jochheim, MDC omplete percutaneous revascularization, in-cluding the treatment of complex lesionsand chronic total occlusions, has become a
frequent reality in interventional cardiology. Although
the overall need for repeat revascularization due to
drug-eluting stent (DES) restenosis remains in single-
digit levels, in highly complex forms of coronary artery
disease, itmay signiﬁcantly compromise the long-term
outcomes (1). Use of a second layer of DES to treat in-
DES-restenosis is feasible and efﬁcacious, but safety
concerns at very long-term follow-up have been raised
(2). Paclitaxel-eluting balloons have been established
as an equivalent alternative to repeat implantation of
ﬁrst-generation DES regarding the antirestenotic efﬁ-
cacy within the ﬁrst year of treatment of in-DES reste-
nosis (3,4).SEE PAGE 1695In this issue of JACC: Cardiovascular Interventions,
Rittger et al. (5) report 3-year results of the PEPCAD-
DES (Treatment of Drug-Eluting Stent [DES] In-Stent
Restenosis With SeQuent Please Paclitaxel Eluting
Percutaneous Transluminal Coronary Angioplasty
[PTCA] Catheter) study. A total of 110 patients pre-
senting with in-DES restenosis were randomly
assigned to be treated with either paclitaxel-coated
balloon (PCB) (n ¼ 72) or plain balloon angioplasty
(POBA) (n ¼ 38). At 9-month angiographic follow-up,
PCB proved superior to POBA regarding the primary*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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relevant to the contents of this paper to disclose.endpoint of late lumen loss (0.43  0.61 mm vs. 1.03 
0.77 mm, p < 0.001, respectively) (6). At 3-year
follow-up, the incidence of target lesion revasculari-
zation (TLR) was 19.4% for PCB-treated patients
compared with 36.8% for POBA-treated patients
(p ¼ 0.046), reﬂecting the early angiographic results.
Cumulative rate of major adverse cardiac events was
20.8%, signiﬁcantly lower with PCB compared with
POBA (52.6%, p ¼ 0.001). Cardiac mortality and
myocardial infarction were also lower with PCB
compared with POBA (2.8% vs. 10.5%, p ¼ 0.089, and
0% vs. 5.3%, p ¼ 0.049, respectively) (5). Although
interesting, the observed differences in safety proﬁle
between both treatment groups are difﬁcult to
explain. The more frequent need for repeat re-
vascularizations in the same patient observed with
POBA (13.2%) compared with PCB (1.4%) may have
contributed to these ﬁndings. Data coming from
larger registries showing an association between
presence of restenosis and increased mortality at very
long-term follow-up support this hypothesis (7). On
the other hand, the small number of patients included
and the 2:1 randomization schema used for treatment
allocation may have been insufﬁcient to adequately
account for cardiac and noncardiac comorbidities.
The PEPCAD-DES study is one among the ﬁrst
studies investigating efﬁcacy of PCB for treatment of
in-DES-restenosis (3,4), but it is the only one having
more than 50% of patients presenting with recalci-
trant restenosis after implantation of at least 2 layers
of stent. However, the observed TLR rate with PCB
(15.3% at 1 year and 19.4% at 3 years) in this very
complex population is still similar to the ones re-
ported in other studies that included mostly patients
with ﬁrst in-DES restenosis (<22% at 1-year follow-up
and up to 36% at 3-year follow-up) (2–5,8). In
the ISAR-DESIRE 3 (Intracoronary Stenting and
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Restenosis 3) trial, 3 treatment strategies for reste-
nosis after implantation of “limus”-eluting stents
were compared: PCB, POBA, and paclitaxel-eluting
stents. The recently published 3-year results of this
study showed that among patients treated with PCB,
nearly 30% of repeat TLR occur after the ﬁrst year
compared with only 14% among POBA-treated pa-
tients (2). In contrast to this, in the PEPCAD-DES
study, only a minority of TLRs occurred after the
ﬁrst year (14% with PCB and 0% with POBA) (5).
There are many possible explanations for these
puzzling ﬁndings. First, differences in all-cause mor-
tality rates were observed in both studies. Three-year
cumulative all-cause mortality was 6.0%with PCB and
9.4% with POBA in the ISAR-DESIRE 3 study, whereas
it was 8.3% with PCB and 13.2% with POBA in the
PEPCAD-DES study (2). For PCB-treated patients, this
means an absolute annual mortality increase of 2% in
the ISAR-DESIRE 3 study and of 3.5% in the PEPCAD-
DES study. This highlights the poorer risk proﬁle of
PEPCAD-DES patients. Second, there were possible
differences in the routine follow-up protocols used in
centers participating in both studies. It is well known
that routine control coronary angiography leads to
increased rates of repeat revascularizations due to
oculostenotic reﬂex. We do not know the rate of
scheduled repeat angiograms between 1 and 3 years in
both studies. However, the fact that the incidence of
TLR between 1 and 3 years was 14% with PCB and
POBA in the ISAR-DESIRE 3 study and <4% in the
PEPCAD-DES study might suggest a higher frequency
of scheduled angiographies during this period in the
ISAR centers. Third, the mechanisms of late DES fail-
ure are very complex. Neoatherosclerosis, a phe-
nomenon that has been observed very late after
implantation of bare-metal stents, but relatively early
after DES implantation (within the ﬁrst year), is one
important mechanism of late DES failure in the form
of stent thrombosis or in-DES restenosis (9). Neo-
atherosclerosis can develop within the restenotic
neointimal tissue, and in itself, it can trigger the in-
DES neointimal hyperplasia. There are no data about
the role of multiple DES layers on the quality of in-DES
restenosis, nor are there data about the relative efﬁ-
cacy of paclitaxel on treatment of neoatheroslerosis or
neointimal hyperplasia alone. Because in both of the
ISAR-DESIRE 3 and PEPCAD-DES studies no intra-
coronary imaging was performed, possible differences
in the quality of in-DES restenosis at randomization in
both studies can only be speculated. Finally, these
ﬁndings can highlight the differences in the degree of
disease severity in both studies, which may lead to
different time courses in re-restenosis occurrence.Focusing on the aggregation of prorestenotic
factors, Rittger et al. (5) performed a quantity of
subgroup analyses stratifying the population accord-
ing to the patients’ age, body mass index, presence of
diabetes mellitus, type of the original stent (pacli-
taxel- or limus-based), single or multiple DES layers,
and restenosis pattern. The size of subgroups ranged
between 13 and 51 patients, which is too small to draw
any meaningful conclusions.
Another limitation of the PEPCAD-DES study is
the lack of a third treatment arm using the current
standard-bearer, the everolimus-eluting stent. Al-
though considering the fact that a great proportion of
enrolled patients in the PEPCAD-DES study under-
went treatment of recalcitrant restenosis, avoidance
of a third metallic layer is conceivable. Evidence is
accumulating toward better 1-year efﬁcacy of the
everolimus-eluting stent compared with PCB when
used for treatment of in-DES restenosis (10). In the
RIBS IV (Restenosis Intra-Stent of Drug-Eluting
Stents: Drug-Eluting Balloon versus Everolimus-
Eluting Stent) trial, which enrolled 309 patients in
23 Spanish centers, the composite of cardiac death,
myocardial infarction, and target vessel revascul-
arization was reduced by more than 40% with
everolimus-eluting stents compared with PCB,
mainly driven by a lower revascularization need
(respectively, 8% vs. 16%, p ¼ 0.035). The angio-
graphic parameters of restenosis were reduced in
nearly all patients’ subgroups, including the ones
deﬁned according to the pattern, time, and location of
restenosis (10). Differing from the PEPCAD-DES
study, in the RIBS IV study, only 12% of patients
underwent treatment of recalcitrant restenosis.
Furthermore, considering the reported safety concern
at long-term follow-up with the paclitaxel-eluting
stent when used for in-DES restenosis (2), longer-
term data are required before adopting a strategy of
everolimus-eluting stent for treatment of all forms of
restenosis.
Adding the ﬁndings of the PEPCAD-DES study to
the available published evidence, we can conclude
that interventional treatment of in-DES restenosis is
far away from a “one size ﬁts all” strategy. A better
understanding of the patients’ restenosis history and
a better characterization of the restenotic tissue by
intracoronary imaging is required for tailoring treat-
ment of in-DES restenosis.
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